Health Catalyst, Inc.
NASDAQ:HCATMedical - Healthcare Information Services
-$0.04 today
- Market cap
- $98.24M
- Beta
- 1.66
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$3.65
Volume 0.27M
Average 1.24M
HCAT Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Health Catalyst, Inc.NASDAQ: HCAT
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -156.9%
Net margin was -156.9% in Q1 FY2026, down 127.0 pp from a year earlier. On a trailing-twelve-month basis it was -87.7%, down 64.4 pp year over year. Over 3 fiscal years it narrowed by 7.5 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of -1.5% for the fiscal year ending Dec 2026, up from -57.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -156.9%-35.0 pp QoQ
- Last fiscal yearDec 2025
- -57.2%-34.5 pp YoY
- LTMMar 2026
- -87.7%-64.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -127.0 pp | +54.0 pp | +181.1 pp |
| 1 year | -34.5 pp | +55.7 pp | +90.2 pp |
| 3 years | -7.5 pp | +59.8 pp | +67.2 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -57.2%
- Year-over-year change
- -34.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -57.2% | -34.5pp |
| FY2024 | 2024-12-31 | -22.7% | +17.3pp |
| FY2023 | 2023-12-31 | -39.9% | +9.8pp |
| FY2022 | 2022-12-31 | -49.7% | +13.6pp |
| FY2021 | 2021-12-31 | -63.3% | — |
Net Margin vs competitors
How HCAT compares with its peers on the latest reported figures
- HCAT's LTM Mar 2026 net margin of -87.7% is the 3rd highest of the 11 companies compared; the peer median is -520.7%.
- Its year-over-year change of -64.4 pp is the 8th highest of 9, against a peer median of +213.9 pp.
- Over three fiscal years its change of -7.5 pp compares with a peer median of +88.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 36.2% | +126.1 pp | +88.3 pp | |
| LTM Mar 2026 | -63.7% | +35.1 pp | +72.9 pp | |
| LTM Mar 2026 | -87.7% | -64.4 pp | -7.5 pp | |
| LTM Mar 2026 | -89.6% | +60.0 pp | +16.0 pp | |
| LTM Mar 2026 | -167.0% | +2130.9 pp | +793.9 pp | |
| LTM Mar 2026 | -465.3% | +1360.8 pp | — | |
| LTM Dec 2025 | -576.1% | -101.8 pp | +650.8 pp | |
| LTM Mar 2026 | -589.8% | — | — | |
| LTM Mar 2026 | -1189.1% | +301.7 pp | -609.6 pp | |
| LTM Mar 2026 | -1427.1% | +1583.0 pp | +1108.5 pp | |
| LTM Mar 2026 | -36891.1% | — | — | |
| Peer median (excluding HCAT) | -520.7% | +213.9 pp | +88.3 pp | |
Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 241.93M | 276.24M | 295.94M | 306.58M | 311.14M |
| Cost of Revenue | 124.35M | 143.05M | 164.11M | 165.81M | 207M |
| Gross Profit | 117.57M | 133.19M | 131.83M | 140.78M | 104.13M |
| Gross Margin | 48.6% | 48.2% | 44.5% | 45.9% | 33.5% |
| Research & Development | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M |
| Selling, General & Admin | 160.96M | 149.22M | 143.88M | 111.2M | 102.04M |
| Operating Expenses | 261.22M | 273.19M | 258.73M | 210.59M | 140.24M |
| Depreciation & Amortization | 41.11M | 51.53M | 42.22M | 41.43M | 50.5M |
| EBITDA | (101.68M) | (82.92M) | (68.28M) | (10.65M) | (110.35M) |
| EBITDA Margin | -42.0% | -30.0% | -23.1% | -3.5% | -35.5% |
| Operating Income | (143.65M) | (140.01M) | (126.9M) | (69.81M) | (36.1M) |
| Operating Margin | -59.4% | -50.7% | -42.9% | -22.8% | -11.6% |
| Interest Income | 831K | 5.69M | 16.39M | 17.98M | 7.54M |
| Interest Expense | 17.31M | 7.24M | 7.29M | 17.09M | 16.4M |
| Other Income / Expenses | (16.46M) | (1.68M) | 9.11M | 637K | (141.15M) |
| Income Before Tax | (160.11M) | (141.68M) | (117.79M) | (69.17M) | (177.26M) |
| Pre-Tax Margin | -66.2% | -51.3% | -39.8% | -22.6% | -57.0% |
| Income Tax Expense | (6.9M) | (4.28M) | 356K | 333K | 716K |
| Net Income | (153.21M) | (137.4M) | (118.15M) | (69.5M) | (177.97M) |
| Net Margin | -63.3% | -49.7% | -39.9% | -22.7% | -57.2% |
| EPS (Basic) | (3.23) | (2.56) | (2.09) | (1.15) | (2.55) |
| EPS (Diluted) | (3.23) | (2.54) | (2.09) | (1.15) | (2.55) |
| Weighted Avg Shares | 47.49M | 53.72M | 56.42M | 60.19M | 69.9M |
| Weighted Avg Shares (Diluted) | 47.49M | 54.08M | 56.42M | 60.19M | 69.9M |
Health Catalyst, Inc.
NASDAQ:HCAT
Intrinsic Alpha fair value
Locked
Current Price
$1.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.